Galectin Therapeutics Inc. (GALT)

Market Cap	216.66M
Revenue (ttm)	n/a
Net Income (ttm)	-44.81M
Shares Out	61.90M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,770
Open	2.990
Previous Close	3.290
Day's Range	3.200 - 3.550
52-Week Range	1.280 - 4.270
Beta	0.88
Analysts	Strong Buy
Price Target	11.00 (+214.29%)
Earnings Date	May 13, 2024

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with nonalcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its G...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT

Analyst Forecast

According to one analyst, the rating for GALT stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(214.29% upside)

Analyst Consensus: Strong Buy